{
  "id": 17951722,
  "title": "JPMorgan initiates TRex Bio stock coverage with overweight rating",
  "url": "https://urgent.news/2026/11/03/jpmorgan-initiates-trex-bio-stock-coverage-with-overweight-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-03T10:50:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-trex-bio-stock-coverage-with-overweight-rating-93CH-4994303"
  },
  "original_language": "en",
  "account": "JPMorgan has started tracking TRex Bio (NASDAQ:TRXB) with an optimistic outlook, bestowing the company an \"overweight\" rating and forecasting a potential share price of $20.00. Analyst Brian Cheng outlined TRex Bio’s unique strategy in regulatory T cell biology, which aims to selectively grow and empower functional tissue Tregs to rebalance the immune system, rather than broadly dampening inflammation. The firm considers this method to be distinct from the competition in the inflammation and immunology sectors. Currently, TRex Bio's shares are trading at $13.64, hovering close to its 52-week low of $13.10, with analyst estimates of up to $30.00. TRex Bio's main drug candidate, TRB-061, a TNFR2 agonist, is being developed for atopic dermatitis, and initial preclinical and healthy volunteer data have demonstrated effective activation of target Treg cells, optimal target engagement, and a positive safety profile. The biotech company boasts a robust financial position, with a current ratio of 12.18 and more cash than debt, as per InvestingPro data, ensuring sufficient resources for clinical development. The next critical step is the first in-patient data from the ongoing Phase 1b atopic dermatitis study, which JPMorgan believes will be the pivotal moment in determining the program's progression into later-stage trials for atopic dermatitis and alopecia areata. TRex Bio's CD30-targeted program and collaborations with pharmaceutical giants Johnson & Johnson and Eli Lilly are currently in the early stages of development. The analyst also anticipates TRex Bio's potential to broaden into other inflammation and immunology opportunities. Recently, Stifel initiated coverage of TRex Bio with a \"buy\" rating, setting a price target of $39.00, based on the company's potential in regulatory T-cell modulation for autoimmune disease treatment. The company's strong genetic, mechanistic, and clinical evidence supporting Treg expansion to clinical outcomes has caught the firm's attention, despite previous approaches within the IL-2 axis being limited by a narrow therapeutic index.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}